The crisis of antimicrobial resistance is driving research into the phenomenon of collateral 17 sensitivity. Sometimes, when a bacterium evolves resistance to one antimicrobial, it becomes 18 sensitive to others. In this study, we have investigated the utility of Phenotype Microarray 19 (PM) plates for identifying collateral sensitivities with unprecedented throughput. We 20 assessed the relative resistance/sensitivity phenotypes of nine strains of Staphylococcus 21 aureus (two laboratory strains and seven clinical isolates) towards the 72 antimicrobials 22 contained in three PM plates. In general, the PM plates reported on resistance and sensitivity 23 with a high degree of reproducibility. However, a rigorous comparison of PM growth 24 phenotypes with minimum inhibitory concentration (MIC) measurements revealed a trade-off 25 between throughput and accuracy. Small differences in PM growth phenotype did not 26 necessarily correlate with changes in MIC. Thus, we conclude that PM plates are useful for 27 the rapid and high-throughput assessment of large changes in collateral sensitivity 28 phenotypes during the evolution of antimicrobial resistance, but more subtle examples of 29 cross-resistance or collateral sensitivity cannot be reliably identified using this approach.
INTRODUCTION
After incubation, growth in each well was scored by eye. Each well was given a score out of 130 2: 0 for colourless (no growth); 1 for light purple (intermediate growth); and 2 for dark purple 131 (full growth). Each antimicrobial was present in four wells at increasing concentrations. 132 Growth scores across the four wells were summed. Maximal resistance therefore 133 corresponded to a growth score of 8, whereas a growth score of 0 corresponded to complete 134 sensitivity. Minimum inhibitory concentrations (MICs) for six antimicrobial compounds were 139 determined by the broth microdilution method, as described previously [17, 20] . The first 140 column of wells in a 96-well plate was filled with 200 µl of MH broth plus the antimicrobial 141 at the maximum concentration to be tested. The remaining wells contained 100 µl MH broth.
142
This was used to begin a two-fold dilution series, which covered 12 concentrations. A 100 µl 143 aliquot from column 1 was transferred into the wells in column 2, pipetted up and down to 144 mix, and repeated for the remaining rows. A 3-µl aliquot of saturated cell culture, diluted to 145 OD 600 = 0.5, was used to inoculate each well. Plates were sealed with a breathable membrane The first well which showed ≥95% inhibition was deemed to be the MIC cut-off for that This study has emphasized the power -and potential pitfalls -of PM plates for the large-303 scale assessment of cross resistance and collateral sensitivity. We were able to rapidly obtain 304 resistance and sensitivity data for 72 antimicrobials, which is many more than have been 305 tested in previous studies [8, 12, 14, 15] . It would be straightforward to expand our approach 306 to more of the antimicrobial-containing PM plates. In total, plates 11-20 contain 237 307 antimicrobials; testing the entire set would represent an order of magnitude increase in 308 screening breadth compared to current approaches. Moreover, scoring PM growth by eye ( Fig   309   1 ) proved to be a fast, technically straightforward, cost effective and reproducible way to 310 collect resistance and sensitivity data. In independent duplicates, carried out several weeks 311 apart, we obtained identical growth scores in 544 of 648 antimicrobial/strain combinations. When PM growth scores were carefully compared with MIC data obtained by broth 318 microdilution, a trade-off between throughput and accuracy became apparent. Small 319 differences in PM growth score did not reliably correlate with MIC. Our data suggest that a 320 difference in growth score of at least 2 points is required to indicate a genuine difference in 321 MIC between two S. aureus strains. For example, the PM assays suggested that many of the 322 MRSA strains were more sensitive to demeclocyline, nickel chloride or 2,2-dipyridyl than 323 the laboratory strain S. aureus ATCC 25923 (Fig 3) . However, the differences in PM growth 324 score were small and the evidence for increased sensitivity was not borne out by MIC testing 325 (Fig 4) . The level of agreement (or disagreement) between PM scores and MICs was 326 comparable for the clinical isolates of MRSA and the laboratory strains S. aureus 25923 and 327 25923evo. For the purpose of discovering novel collateral sensitivities, the power of these 328 assays appears to be limited to detecting large reductions in resistance. With one exception 329 (MRSA-SY in oxacillin), differences of 16-fold in MIC between any two strains were 330 always correlated with differences in PM growth.
Our results build on previous findings that laboratory strains are not necessarily good models 333 for exploring collateral sensitivity in the clinical setting [12, 26] . Our laboratory-evolved, 334 oxacillin-resistant strain 25923evo frequently behaved closer to its parent, S. aureus ATCC 335 25923, than to the clinical MRSA isolates. Collateral sensitivities could not be extrapolated 336 from 25923evo to the MRSA isolates, either from PM results or from MIC data. 
